The prevalence of obesity is rising at an alarming rate worldwide, with consequent increases in type 2 diabetes, hypertension and cardiovascular mortality. Despite this, the biological mechanisms predisposing to weight gain in humans remain poorly understood.
Based on findings in animal models of obesity, the sympathoadrenal system has commonly been assumed to have a determining role in obesity development, through its influence on regulation of energy expenditure. A widely held view (3, 33) has been that reduced sympathoadrenal activity, by leading to diminished thermogenesis, underlies the development of obesity. While more recent evidence indicates that sympathetic nervous activity is actually increased in human obesity (13) , the case is still open for an importance of adrenal medullary secretion of epinephrine in contributing to the development of obesity (49) .
The function of the sympathoadrenal system and the adipocyte hormone, leptin (50), appear to be intimately linked (5) . In rodents leptin promotes weight loss by reducing appetite and through increasing sympathetically mediated energy expenditure (43).
Experimental evidence exists of a two-way interaction between leptin and the sympathetic nervous system, perhaps constituting a regulatory feedback loop, with leptin acting within the hypothalamus to cause activation of central sympathetic outflow, and conversely, with the sympathetic nervous system inhibiting leptin release from white adipose tissue (42), although recently we found the strength of this latter relation in humans to be weaker than anticipated (7) .
At one time it was assumed that adipocytes are the sole site of leptin production and release. Evidence from studies in experimental animals and humans now indicates that leptin is also derived from non-adipose sites (1, 14, 29) , one of these being the brain (14, 29) . This putative brain leptin system remains very incompletely categorised, and E-00489-2003.R2 possible relationships to other brain neuronal systems regulating feeding behaviour and energy expenditure are largely unexplored. Neuropeptide Y (NPY) concentration is increased in the hypothalamus in some experimental genetic models of obesity (47) , and NPY has been implicated in the effects of leptin on feeding behaviour (36). Brain serotonergic mechanisms have also been linked experimentally with the CNS actions of leptin (16, 48) . The hypothalamus is highly innervated by serotonin-containing fibres and serotonergic system has been the target of a number of drugs aiming to regulate body weight (25).
In the present study we have explored these issues further, concentrating in particular on the interplay between the sympathoadrenal system and leptin, and on brain leptin, NPY and serotonin mechanisms in human obesity. We tested whether an association existed between rates of leptin secretion, which we estimated from leptin renal clearance rates, and regional sympathetic nervous activity. Whether reduced adrenal medullary secretion of epinephrine might be present in obesity, perhaps contributing to its development (24, 49), was tested by determining epinephrine secretion rates in lean and obese men by isotope dilution methodology (11) . We used simultaneous arterio-venous blood sampling to quantify leptin release to plasma from individual organs, including internal jugular venous blood sampling to test for leptin efflux from the brain (14). We also tested for neuropeptide Y (NPY) jugular venous overflow in obesity, which is not present in lean men (30), and quantified brain serotonin turnover from the rate of jugular overflow of the major metabolite of serotonin, 5-hydroxyindole acetic acid (5-HIAA)(21).
Methods

Subject characteristics
22 lean and 20 obese healthy male volunteers were recruited from the general community for the study. The lean men had a body mass index (BMI) of less than 26,
the obese men had a BMI above 28. The study was confined to men to avoid the confounding influence of gender on leptin values. All participants had thorough clinical evaluation and serum biochemistry measurements to exclude hepatic and renal dysfunction. All research volunteers were unmedicated, and those with a history of cardiovascular disease, diabetes, a blood pressure greater than 140/85 mm Hg, obstructive sleep apnea or an alcohol intake of more than two standard drinks per day were excluded from the study. All subjects had been weight stable (±1 kg) for at least two months prior to the study, while lean subjects did not have a prior history of obesity.
Characteristics of the two groups are summarised in Table 1 . Participation in the study was after written informed consent, with the approval of the Alfred Hospital Ethics Review Committee.
A separate subset of 9 lean and 5 obese male volunteers with normal blood pressures was used to quantify jugular overflow of neuropeptide Y (NPY).
Catheter procedure
All studies were performed after an overnight fast. The subjects were asked to refrain from caffeinated beverages and alcohol for the 12 hours preceding the catheter study.
The catheter procedure was performed with the subjects in the supine position. In a research cardiac catheterisation laboratory, a 21-gauge cannula was introduced percutaneously under local anesthesia into the brachial or radial artery of either arm for blood sampling. In the same arm, an 8.5 French gauge introducer sheath was inserted percutaneously into the median antecubital vein. Venous catheterisation was performed via this sheath. The coronary sinus, renal vein, internal jugular vein and hepatic vein were reached by maneuvring this single central catheter under direct fluoroscopic control. In the internal jugular vein, the catheter tip was above the angle of the jaw, to exclude sampling from the tissues of the face. Correct positioning of the catheter was confirmed using 2mL radiopaque contrast medium.
In all studies, 10-mL blood samples for measurement of the chemicals of interest were obtained simultaneously from the arterial and venous catheters and immediately placed into ice-chilled tubes containing glutathione as antioxidant, and EGTA as anticoagulant.
At the completion of the catheter study and within 15-75 min of sampling, the blood samples were centrifuged at 4 o C and the plasma stored at -80 °C until assayed.
Plasma catecholamine assays
Plasma catecholamine concentrations were determined by high performance liquid chromatography with electrochemical detection (HPLC) (28). Timed collection of the eluate leaving the detection cell with a fraction collector permitted separation of 3 Hlabelled norepinephrine and epinephrine for counting by liquid-scintillation spectroscopy. Intra-assay variations were 4.6% for plasma norepinephrine and 6.8% for plasma epinephrine at concentrations of 150 pg/ml and 7.2% and 6.5% for 3 H-labelled norepinephrine and epinephrine.
Measurement of norepinephrine and epinephrine plasma kinetics
Whole-body, renal and cardiac norepinephrine (NE) spillover rates were determined as measures of sympathetic activity (11) . Subjects were infused with levo-7-3 Hnorepinephrine (New England Nuclear, Boston, MA), specific activity 11-25 Ci/mmol, at a rate of 0.6-0.8 µCi/min. At steady state, whole-body NE spillover to plasma was determined from arterial sampling using isotope dilution. Epinephrine secretion rates were determined similarly (11) , from arterial sampling during the infusion of levo-7-3 Hepinephrine (New England Nuclear, Boston, MA), specific activity 69-78 Ci/mmol, at a rate of 0.6-0.8 µCi/min.
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Regional NE spillover from the heart and kidneys was calculated from the venoarterial plasma NE concentration difference across the organ in question, the fractional extraction of radiolabeled NE occurring in transit, and regional plasma flow (11) .
Coronary sinus and internal jugular plasma flows were derived from thermodilution blood flow measurements and the hematocrit (12), renal plasma flow was determined from the clearance of infused p-aminohippuric acid, while hepatic blood flow was quantified from the clearance of indocyanine green.
Plasma leptin assay
Total plasma leptin levels were measured in duplicate by radioimmunoassay (Linco Research, Inc., St. Charles, MO), with an intra-assay coefficient of variation of 5%, and a sensitivity of 0.5 ng/ml. Renal leptin clearance was calculated as the product of the fractional extraction of plasma leptin in transit through the kidney and renal plasma flow. Whole-body leptin secretion rate was calculated as the product of arterial plasma leptin concentration and renal leptin clearance. The rate of release of leptin from the brain was calculated from the product of the internal jugular-arterial venoarterial plasma leptin concentration difference and the internal jugular plasma flow.
Measurement of whole body leptin release to plasma
Since clearance of leptin from plasma is almost exclusively by renal removal [Cumin, 1997 #79] , by applying the principal of the conservation of mass we estimated the rate of whole-body leptin release to plasma at steady state from measurements of renal leptin extraction from plasma in transit through the kidneys, utilising renal vein sampling.
Renal leptin extraction was derived from the product of the arterial plasma concentration of leptin and leptin renal plasma clearance.
Plasma 5-HIAA assay
The plasma concentration of the major serotonin metabolite, 5-HIAA, was determined by HPLC, as previously described (20). Brain serotonin turnover was calculated from the product of the internal jugular-arterial venoarterial plasma 5-HIAA concentration difference and the internal jugular plasma flow (21).
Plasma NPY assay
NPY-like immunoreactivity (NPY-LI) concentration was determined by radioimmunoassay of plasma samples and NPY standards, as previously described (30).
Chromatographic characterisation of the NPY-LI detected in human plasma was carried out by HPLC separation using a linear acetonitrile gradient. The rate of release of NPY from the brain was calculated from the product of the internal jugular-arterial venoarterial plasma NPY concentration difference and the internal jugular plasma flow.
Statistical analysis
Statistical analyses were performed using SigmaStat for Windows Version 2.03 (Jandel Scientific, San Rafael, CA) using a Student's t-test and ANOVA, where appropriate. If normality or equal variance failed, Mann-Whitney Rank Sum test was employed. Data are expressed as mean ± SEM. Significance was set at P<0.05.
Results
Epinephrine plasma kinetics in obesity
No differences were found in epinephrine plasma kinetics values between lean and obese men. Epinephrine secretion rates were similar in the two groups ( Figure 1 ).
Regional sympathetic nervous system activity in obesity
Renal norepinephrine spillover, indicative of renal sympathetic activity (32), was significantly higher in obese, 150.3±30.6 ng/min, than lean men, 64.2±13.0; p=0.013 (Table 1 ). The higher renal norepinephrine spillover in the obese was not attributable to
greater wash-out of the transmitter from an elevated renal blood flow, as mean renal plasma flows were similar in obese and lean men, 813 ml/min and 718 ml/min respectively (difference not statistically significant). Whole-body norepinephrine spillover rates were similar in the two groups. While norepinephrine spillover from the heart tended to be decreased in obese subjects, this did not reach statistical significance (Table 1) .
Whole-body leptin secretion rates
Renal clearance of leptin was 135±26 ml/min, equating to a removal rate of 1245±396 ng/min, which was the estimated leptin secretion rate ( Figure 2 ).
Whole-body leptin secretion in obesity
As expected, arterial plasma leptin concentrations were significantly higher in obese than lean men, 10.2±1.2 ng/ml vs. 
Linkage between leptin secretion rate and sympathetic nervous activity
In lean and obese subjects combined, whole-body leptin secretion was unrelated to adrenal medullary secretion of epinephrine or to cardiac norepinephrine spillover ( Figure   4 ). In contrast, a statistically significant direct relationship of low order was evident between leptin secretion rate and total norepinephrine spillover, the measure of overall sympathetic nervous system activity (r=0.498, P<0.05). The statistical significance of this relationship disappears with omission of the outlier with highest total norepinephrine spillover rate. A stronger relationship was present with renal norepinephrine spillover (r=0.66, P<0.001) (Figure 4 ).
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Regional leptin kinetics and extra-adipocyte leptin release to plasma There was no net input of leptin to plasma from the heart or hepatomesenteric circulation (Figure 2)( Table 2) . A step-up in the plasma concentration of leptin was present across the brain circulation (Table 2) . Unilateral jugular leptin spillover was 264±87 ng/min. Total brain leptin release to plasma was taken to be twice this value, 529±175 ng/min (46) .
Based on the value for whole-body leptin secretion, 1245±396 ng/min, with subtraction of regional leptin fluxes across the brain, heart and hepatomesenteric circulation, a maximum value of adipocyte-derived leptin release to plasma for all subjects combined was estimated to be 716.4 ng/min ( Figure 2 ). This figure relies on the assumption that inputs to plasma from the lungs, skeletal muscle and the urogenital system are small and can be discounted.
Brain leptin overflow in obesity
The unilateral rate of overflow of leptin from the brain into an internal jugular vein was significantly greater in obese, 467±160.4 ng/min, than lean men, 80.0±29.3; p=0.045. possible for brain NPY overflow measurements, which were made in the absence of leptin and serotonin turnover measurements, in a different patient subset.
Discussion
We have investigated here regional leptin production in obese men and examined its relationship with norepinephrine turnover.
Reduced Catecholamine Thermogenesis Hypothesis
The sympathoadrenal system is an important contributor to the regulation of energy expenditure, and based primarily on results derived from experimental models of obesity (38) reduced sympathetic nervous activity and epinephrine secretion has been assumed to play a major role in the development of human obesity (3). Although some clinical studies have given support to the idea of reduced sympathoadrenal activity in the pathogenesis of obesity (33), recent evidence derived from sympathetic nerve recordings (clinical microneurography) (15) and from measurement of norepinephrine spillover (13) does not support the earlier claims. While whole-body norepinephrine spillover rates in obese humans with normal blood pressure are unremarkable, sympathetic neural outflow to the kidneys and to the skeletal muscle vasculature is increased (13, 15) . Our findings here of unremarkable total norepinephrine spillover rates in obese men, increased norepinephrine spillover from the kidneys, accompanied by somewhat reduced cardiac norepinephrine spillover conform well with the earlier observations (35).
While the present results and other more recent evidence from studies in human obesity indicate that sympathetic nervous activity is actually increased in human obesity (13) 
Whole-body leptin secretion
Since clearance of leptin from plasma is primarily by renal removal (4), at steady state while fasting we could estimate the rate of whole-body leptin release to plasma from renal leptin excretion, derived from measurement of leptin extraction from plasma in transit through the kidneys, utilising renal vein sampling. Perhaps not surprisingly, the estimated whole-body leptin secretion rate was significantly elevated (5-fold increase) in the obese men. Mean renal clearance of leptin was similar in obese and lean men (156±41 and 110±29 ml/min, respectively), making no contribution to the higher plasma leptin concentrations which characterises obesity.
Links between whole-body leptin secretion and sympathetic nervous activity
Leptin and the sympathoadrenal system appear to be intimately linked (5) . It has been suggested that there may be a two-way interaction between leptin and the sympathetic nervous system, perhaps constituting a regulatory feedback loop, with leptin acting within the hypothalamus to cause activation of central sympathetic outflow and stimulation of adrenal medullary release of epinephrine (9), and conversely, with the sympathetic nervous system inhibiting leptin release from white adipose tissue (42).
Increases in sympathetic outflow to the kidneys, adipose tissue and the skeletal muscle vasculature, and in the neural traffic to the adrenal gland are well documented following leptin administration intravenously and intracerebroventricularly in experimental animals (6, 8, 17) . The effect of leptin infusions on sympathetic activity in humans, however, has not been definitively studied to this point, although daily subcutaneous injections of leptin were without effect (26). Given this uncertainty, we evaluated whether an association existed between regional sympathetic activity and whole-body leptin secretion rate in the lean and obese men studied.
Whole-body leptin secretion was elevated in the obese men. Of measures of sympathoadrenal function measured, both total and renal norepinephrine spillover rates correlated directly with the whole-body leptin secretion rate. Although this cross sectional data, perhaps, suggests that hyperleptinemia may be the prime mover underlying the sympathetic nervous activation present in human obesity, given the experimental evidence from leptin administration in rodents (6, 8, 17) , any causal link in humans is, at best, no more than suggestive, and more compelling and direct results would be needed to definitively establish leptin as a driving force in the renal sympathetic activation of human obesity and obesity-related hypertension. It should also be stated that the association we note here, of sympathetic activity with total plasma leptin levels, may not exist for free plasma leptin (39). Hyperinsulinemia (23) and obstructive sleep apnea (31), both common in obesity, have also been proposed as mechanisms of the sympathetic activation present. Obstructive sleep apnea was not obvious in these patients from interview of them and their partners, but sleep laboratory monitoring was not performed. The possibility of age being a significant confounder in the present study by contributing to the sympathetic activation in the obese, given that they were on average 8 years older than the lean men (a statistically non significant difference), can be discounted. The influence of an age difference of less than ten years on sympathetic activity is very much smaller than what we observe here (37).
Adipocyte and extra-adipocyte release of leptin
Evidence from studies in experimental animals and humans indicates that leptin is released, in addition to adipocyte release, from multiple non-adipose sites (1, 14, 29 In contrast to our previous report (45), we found trifling release only of leptin from the heart. No basis for this different finding is apparent other, perhaps, than that the present study was confined to men. Similarly, there was no net release of leptin into the hepatomesenteric circulation, leptin concentrations being identical in arterial and hepatic venous plasma. Although this was unexpected, it being thought that there would be substantial leptin release from omental adipose tissue, the finding is in agreement with an earlier report based on central venous catheter sampling from the hepatic vein in humans (18) . There are, however, two factors that might confound our observation of an absence of leptin overflow into the hepatic vein. First, it is possible that leptin released from omental adipose tissue might have been cleared from plasma during passage through the liver, although no direct confirmation of hepatic clearance of plasma leptin is available as yet. Hepatic clearance of leptin, if it exists, might materially reduce the contribution of the omentum to systemically circulating leptin. In addition, there is a second, technical caveat, namely that the high blood flow through the liver, by minimizing arteriovenous plasma leptin concentration differences, could cause measurement error.
The rate of release of leptin to plasma by adipocytes was estimated by subtracting measured regional leptin production rates from the whole-body leptin secretion rate, specifically those for the brain, heart, kidney and hepatomesentric circulation. In this derivation we discounted any leptin production by the lungs, skeletal muscle and urogenital system. There does appear to be no pulmonary leptin production (18), but assuming a negligible contribution by skeletal muscle and the urogenital system is perhaps problematic. As anticipated, the derived leptin release rate for adipose tissue was markedly elevated in obesity. This increase in leptin production rate appears to be due both to an increase in fat cell number, and to overexpression of leptin by adipocytes (19).
Influence of obesity on release of leptin from the brain
Leptin overflow from the human brain has previously been demonstrated to be influenced by gender, being greater in women (46) . We here confirm an earlier preliminary finding (46) , that an additional influence is adiposity, leptin release from the brain to plasma being markedly higher in obese than lean men. The notion that leptin resistance might exist in human obesity due to a failure of leptin to enter the brain and access its sites of action in the hypothalamus would now seem to be unlikely, given
direct experimental evidence of brain production of leptin (29) and our observation here in humans of leptin release from the brain.
Increased brain serotonin turnover in obesity
We quantified brain serotonin turnover, from the rate of overflow of the major metabolite of serotonin, 5-hydroxyindole acetic acid (5-HIAA) into the internal jugular veins, using our previously established methods (21). Brain serotonergic mechanisms have been linked experimentally with the CNS actions of leptin (16, 48) . Mutant mice lacking functional 5-HT 2 C receptors are overweight due to an abnormality in feeding behaviour (41). The hypothalamus is highly innervated by serotonin-containing fibres and serotonergic system has been the target of a number of drugs aiming to regulate body weight (25). In humans selective serotonin re-uptake inhibitors, when used in patients with depressive illness and panic disorder, commonly cause substantial weight gain (27).
Using our jugular venous sampling method for quantifying whole brain serotonin turnover we have previously been able to detect brain serotonergic neuronal systems responsive to light (21), and anxiogenic serotonergic neuronal pathways activated in patients with panic disorder (10). We here confirm our earlier preliminary finding (22) of, additionally, activation of serotonergic neuronal pools in obesity, presumably those involved in feeding and satiety responses.
Release of NPY from the brain in obesity
NPY concentration is increased in the hypothalamus in some experimental genetic models of obesity (2) , and neuronal NPY in the arcuate nucleus has been implicated in the effects of leptin on feeding behaviour. Previously we have reported that there is no overflow of NPY from the brain to plasma in lean men (30), and confirm this in the present study. In contrast, brain release of NPY to plasma was evident in obese men.
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These results indicate that leptin is released within the brain, and at an increased rate in obese humans, in whom activation of brain serotonergic and NPY mechanisms also exists.
Although leptin release from the brain and brain serotonin turnover were greater in obese men, there was a nonsignificant trend only for interindividual correlation between these two variables, which argues against a close causal link. No similar inference concerning the presence or absence of a causal relation of brain NPY release to brain leptin release and serotonin turnover is possible, as NPY was measured without accompanying leptin and serotonin measurements in a separate patient subset. 
